Skip to content
DataLookout
Menu

NCT07908134

Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and tolerability: Treatment-emergent adverse events (TEAEs)
Timeframe: Predose on Day 1 until 72 hours following the last study drug administration on Day 7.

Arms and interventions

NRL-1049 50 mgActive comparator

2 × 25 mg IR capsules

NRL-1049 100 mgActive comparator

100 mg: (1 × 25 mg) + (1 x 75 mg) IR capsules

NRL-1049 150 mgActive comparator

150 mg: 2 × 75 mg IR capsules

NRL-1049 200 mgActive comparator

200 mg: (2 × 25 mg) + (2 × 75 mg) IR capsules

NRL-1049 250 mgActive comparator

250 mg: (1 × 25 mg) + (3 × 75 mg) IR capsules

PlaceboPlacebo comparator

Placebo-to-match NRL-1049 capsules (identical size and appearance as the respective NRL-1049 product strength)

Drugs: NRL-1049, Placebo